| Ytd | 7.76% | |
| 1y | 119.59% |
| Open | 22.66 | Prev Close | 22.64 | Low | 22.66 | High | 22.83 | Mkt Cap | 2.01B |
| Vol | 0.00 | Avg Vol | 1.97M | EPS | -2.79 | P/E | -8.11 | Forward P/E | -45.13 |
| Beta | 0.37 | Short Ratio | 9.13 | Inst. Own | 117.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 20.45 | 200-d Avg | 20.19 | 1yr Est | 39.00 |
SNDX News
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors?
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SND
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Le
Syndax Pharmaceuticals NASDAQ: SNDX used a company R&D event to outline expansion plans for its appr
The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical rese
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stag
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeu
Syndax has transitioned into a two-product commercial oncology company with growing revenue and stro
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or K
– High response rates observed with the all-oral combination in a heavily pretreated population, inc
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stag
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX),
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stag
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and mu
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.